MILAN, Italy and DAYTON, Ohio, May 17 /PRNewswire/ -- Eurand, a global specialty pharmaceutical company, announced today the pricing of its initial public offering of 7 million Ordinary Shares at $16.00 per share (before underwriting discounts and commissions). In addition, Warburg Pincus Equity Partners, L.P. and its affiliates, Warburg Pincus Ventures International, L.P. and Gearoid Faherty, Eurand's Chief Executive Officer, have granted the underwriters an option to purchase a maximum of 1.05 million Ordinary Shares to cover over-allotments, if any.
Eurand's Ordinary Shares will trade on the Nasdaq Global Market under the symbol "EURX" and the offering is expected to close on May 22, 2007.
Deutsche Bank Securities Inc. and Lehman Brothers Inc. acted as joint bookrunners and representatives of the underwriters. Banc of America Securities LLC, Lazard Capital Markets LLC and Thomas Weisel Partners LLC acted as co-managers.
The offering of Ordinary Shares is made solely by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained by contacting the prospectus department at (a) Deutsche Bank Securities Inc. by telephone at: 800-503-4611, by email at: firstname.lastname@example.org or by mail at: Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Jersey City, NJ 07311 or (b) Lehman Brothers Inc. by telephone at: 1- 888-603-5847, by email at: email@example.com, by mail at: Lehman Brothers, c/o Broadridge, 1155 Long Island Avenue, Edgewood, NY 11717 or by fax at 631-254-7268.
A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Eurand is a specialty pharmaceutical company with facilities in Milan and Trieste, Italy; Philadelphia, Pennsylvania and Dayton, Ohio, USA; and Paris, France.
Source: Eurand, Inc.
>>> Discuss This Story